Bioventus And 3 Other Stocks Under $5 Insiders Are Buying

The Dow Jones closed lower by 175 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Matterport

• The Trade: Matterport, Inc. MTTR Director Jason Krikorian acquired a total of 100,000 shares an average price of $2.46. To acquire these shares, it cost around 245,940.
• What’s Happening: Matterport joined LOT Network, the world's largest patent licensing platform and non-profit community of global companies committed to protecting themselves against costly litigation from patent assertion entities (PAEs).
• What Matterport Does: Matterport Inc is a spatial data company focused on digitizing and indexing the built world.

Latham Group

• The Trade: Latham Group, Inc. SWIM CEO Michael Scott Rajeski acquired a total of 8,000 shares at an average price of $3.96. The insider spent around $31,680.
• What’s Happening: Latham Group reported better-than-expected second-quarter revenue results.
• What Latham Group Does: Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand.

Bioventus

• The Trade: Bioventus Inc. BVS Interim CEO Anthony Bihl III acquired a total of 39,885 shares at an average price of $4.14. To acquire these shares, it cost around $165,076.
• What’s Happening: Bioventus posted better-than-expected quarterly results.
• What Bioventus Does: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process.

Check This Out: Top 5 Industrials Stocks Which Could Rescue Your Portfolio For August

Don’t forget to check out our premarket coverage here

Entera Bio

• The Trade: Entera Bio Ltd. ENTX Director Sean Ellis acquired a total of 40,000 shares at an average price of $0.60. The insider spent $24,000 to buy those shares.
• What’s Happening: The company said net loss was $4.5 million, or $0.16 per ordinary share, for the six months ended June 30, 2023.
• What Entera Bio Does: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins.